WebDoctor Encyclopedia

Genitourinary

Urethral cancer

Urethral cancer is a rare cancer of the tube that carries urine out of the body. It mainly affects people over 60, often causes bleeding or difficulty passing urine, and is treated with surgery, radiotherapy and chemotherapy depending on stage, site and cell type.

Medically reviewed Last reviewed October 20, 2026

What is urethral cancer?

Urethral cancer is a rare cancer of the urethra, the narrow passage through which urine leaves the body after it is released from the bladder. In women the urethra is short, about 4 cm, and opens just above the vagina. In men it is much longer, running through the prostate and along the penis.

When the cancer starts in the urethra itself, doctors call it primary urethral carcinoma. This is different from bladder cancer that later spreads into the urethra, which is more common. Primary urethral cancer makes up far less than 1% of all cancers (Gakis et al., 2013), so most hospitals see only a few cases each year.

Several kinds of cell line the urethra, and each can give rise to a different type of cancer. The main ones are urothelial carcinoma, squamous cell carcinoma and adenocarcinoma. The type found most often depends on the person’s sex and on which part of the urethra is affected.

The disease is most common in people over 60. Early symptoms such as blood in the urine, a weak stream or a lump can be mistaken for infection or a narrowing of the urethra. Treatment depends on the stage, position and type of cancer and on whether the person is male or female. It may involve surgery, radiotherapy and chemotherapy, often in combination (Janisch et al., 2019).

1. Key facts at a glance

Feature Details
What it is Cancer that starts in the lining of the urethra
How common Very rare; well under 1% of cancers
Typical age Usually over 60
Who is affected Both sexes; types and treatment differ between men and women
Main types Urothelial carcinoma, squamous cell carcinoma, adenocarcinoma
Common symptoms Blood in the urine, difficulty passing urine, a lump or discharge
Key imaging test MRI of the pelvis
Main treatments Surgery, radiotherapy and platinum-based chemotherapy
Outlook Good for small, early tumours; poorer when advanced

2. Types of urethral cancer

By cell type

Type Where it usually arises Notes
Urothelial (transitional cell) carcinoma The prostatic and posterior urethra in men; the part near the bladder in women Often linked with bladder cancer
Squamous cell carcinoma The front part of the urethra in men; the outer urethra in women Linked with chronic irritation and HPV
Adenocarcinoma Glands around the urethra, especially in women Includes clear cell and Skene gland types
Rare types Melanoma, sarcoma, neuroendocrine carcinoma Very uncommon

In women, adenocarcinoma is now reported as the most common type (Lagarde-Lenon and Aron, 2022).

By position

Part of the urethra Men Women Lymph node drainage
Anterior (front, distal) Penile urethra Outer third Groin (inguinal) nodes
Posterior (back, proximal) Bulbar and prostatic urethra Inner two-thirds Pelvic nodes

Cancers near the opening tend to be found earlier and do better than those deeper inside.

Urethral cancer after bladder removal

People who have had the bladder removed for bladder cancer, but kept the urethra, can later develop cancer in the remaining urethra. This is called secondary urethral cancer and is checked for during bladder cancer follow-up.

3. Causes and risk factors

Risk factor Notes
Older age Risk rises after 60
Chronic inflammation Repeated infections or long-term catheter use
Urethral stricture Narrowing from scarring, especially in men
Sexually transmitted infections Including human papillomavirus (HPV)
Urethral diverticulum A pouch off the urethra in women; can harbour adenocarcinoma
Previous bladder cancer Linked to urothelial carcinoma of the urethra
Previous pelvic radiotherapy Small increase in risk
Smoking Increases the risk of urothelial cancers

A population study of 453 people found differences between the sexes in tumour type and stage. For example, women were more likely to have adenocarcinoma and men more likely to have squamous or urothelial types (Wei et al., 2017).

4. How does it look

On examination

Feature Description
At the urethral opening A red, raised, wart-like or ulcerated growth
Along the penis A firm lump felt along the underside
In women A mass at or around the urethral opening, or felt through the vaginal wall
Groin Enlarged, firm lymph nodes in advanced cases

On cystoscopy

Looking inside with a cystoscope may show a papillary (frond-like) growth, a flat red patch, or an area of narrowing that bleeds easily.

On MRI

MRI of the pelvis is the preferred test to judge how far the tumour has grown into surrounding tissue (Gakis et al., 2013). It shows the tumour’s depth and its relationship to the penis, prostate, vagina, bladder neck and pelvic floor.

Under the microscope

Type Appearance
Urothelial carcinoma Cells like bladder lining, in sheets or papillary fronds
Squamous cell carcinoma Flattened cells, often with keratin
Adenocarcinoma Gland-forming cells; clear cell type has pale cytoplasm

5. Symptoms

Common symptoms

  • Blood in the urine or blood from the urethra
  • Difficulty passing urine, a weak or split stream
  • Needing to pass urine often or urgently
  • Pain or burning when passing urine
  • A lump or thickening along the urethra or penis

Less common symptoms

Symptom What it may mean
Discharge from the urethra Tumour or associated infection
Swollen glands in the groin Spread to inguinal lymph nodes
Pain during sex Tumour near the vagina or penis
Inability to pass urine Complete blockage
A fistula Abnormal opening between the urethra and skin or vagina

When to seek medical advice

See a doctor if you notice blood in your urine, a new lump on the penis or around the urethral opening, or urinary symptoms that do not settle with treatment for infection. These are much more often caused by other conditions, but they should be checked.

6. Diagnosis

Test Purpose
Physical examination Including the genitals, groin nodes and, in women, a pelvic examination
Urine tests Infection and abnormal cells
Urethrocystoscopy Looks directly at the urethra and bladder
Biopsy Confirms the cancer and its type
MRI of the pelvis Shows local extent
CT of the chest, abdomen and pelvis Checks lymph nodes and distant spread
Fine needle aspiration of groin nodes If nodes are enlarged

Other cancers can look the same under the microscope, so doctors also check for bladder, prostate, cervical, vulval or bowel cancers that may have spread to the urethra.

Staging

Urethral cancer is staged using the TNM system.

Component What it describes
T (tumour) Depth: lining only, into supporting tissue, into the spongy tissue of the penis or the prostate, or into nearby organs
N (nodes) Spread to groin or pelvic lymph nodes
M (metastasis) Spread to distant organs such as the lungs, liver or bone

7. Treatment

A specialist multidisciplinary team should plan care, including urologists, radiation oncologists and medical oncologists.

Early-stage cancer

Situation Treatment options
Small tumour at the front of the urethra (men) Organ-sparing surgery, removing the tumour or part of the urethra and keeping the penis
Small tumour in women Local excision or radiotherapy for tumours at the opening; complete removal of the urethra is often advised to lower the risk of positive margins
Non-invasive urothelial cancer of the prostatic urethra Endoscopic removal (transurethral resection) plus BCG treatment
Small tumour in people who decline surgery Radiotherapy, including brachytherapy

Organ-sparing surgery is reasonable when clear margins can be achieved (Gakis et al., 2013). A review found that radiotherapy alone generally gave poorer control than surgery in localised disease (Janisch et al., 2019).

Locally advanced cancer

Approach Notes
Chemotherapy before surgery Platinum-based combinations can improve survival
Radical surgery May include removal of the urethra, bladder and prostate in men, or the urethra, bladder and part of the vagina in women
Chemoradiotherapy Radiotherapy with chemotherapy, particularly for squamous cell carcinoma
Lymph node dissection Removes groin or pelvic nodes

Combining treatments works better than any single treatment for advanced tumours (Janisch et al., 2019).

Chemotherapy choices by cell type

Cell type Typical regimens
Urothelial carcinoma Cisplatin combinations such as gemcitabine-cisplatin
Squamous cell carcinoma Cisplatin with 5-FU, often with radiotherapy
Adenocarcinoma Regimens similar to those used for bowel or gynaecological cancers

Spread to distant organs

Treatment aims to control the cancer and symptoms. Options include chemotherapy, immunotherapy with checkpoint inhibitors and, for urothelial cancer, newer drugs such as enfortumab vedotin. Clinical trials are encouraged.

Urine diversion after surgery

Option Description
Perineal urethrostomy Urine passes through a new opening behind the scrotum; men then sit to pass urine
Ileal conduit Urine drains through a stoma into a bag
Continent diversion An internal pouch emptied with a catheter
Neobladder A new bladder made from bowel, in selected people

Side effects

Treatment Possible side effects
Surgery Changes to urination, sexual function and body image
Radiotherapy Urethral narrowing, bladder irritation, skin soreness, vaginal dryness
Chemotherapy Tiredness, nausea, infection risk, kidney or hearing effects with cisplatin

What treatment involves day to day

Stage What to expect
Local excision Often a short hospital stay; a catheter for several days
Radical surgery About 1-2 weeks in hospital; weeks of recovery at home
Radiotherapy Weekday sessions for around 5-7 weeks, or a short hospital stay for brachytherapy
Chemotherapy Usually 3-4 cycles before surgery, each lasting 3 weeks

8. Outlook (prognosis)

The outlook depends mainly on stage. Small tumours near the opening can often be cured. Cancers that have grown deep or reached lymph nodes are harder to treat.

Factor Effect on outlook
Low stage Good outlook
Anterior (front) position Better than posterior
Lymph node involvement Poorer survival
Distant spread Poor outlook
Older age Shorter overall survival
Treatment with surgery Linked with longer survival in women in one population study (Wei et al., 2017)

9. Follow-up

Follow-up Purpose
Clinic review and examination every 3-6 months Checks for local recurrence
Cystoscopy or urethroscopy Looks at the remaining urethra and bladder
Urine cytology For urothelial cancers
MRI or CT Checks the pelvis, nodes and lungs
Groin examination For nodal recurrence

10. Living with urethral cancer

  • Learn how to care for a stoma or catheter if you have one; specialist nurses can help
  • Drink enough fluids to keep urine flowing
  • Report bleeding, infection or a weak stream promptly
  • Ask about sexual health support; changes after treatment are common and help is available
  • Do pelvic floor exercises if advised
  • Stop smoking to reduce the risk of further urothelial cancers
  • Seek support from urology cancer charities and counselling services

11. Frequently asked questions

Question Answer
Is it the same as bladder cancer? No, though urothelial urethral cancer is related and they can occur together
Is it caused by HPV? Some squamous cell carcinomas are linked to HPV
Will I still be able to have sex? Often yes after organ-sparing treatment; more radical surgery can affect sexual function
Will I need a urine bag? Not always; it depends on the operation
Can radiotherapy be used instead of surgery? For some small tumours, especially in women
Is it more common in men or women? It occurs in both; types and treatments differ
Can it come back? Yes, so regular follow-up is important

12. Questions to ask your care team

  • What type of urethral cancer do I have, and where exactly is it?
  • What is the stage, and have the lymph nodes been checked?
  • Is organ-sparing treatment possible?
  • Would chemotherapy before surgery help me?
  • How will treatment affect urination and sexual function?
  • Who can help me if I need a stoma?
  • How often will I need check-ups?
  • Is this hospital experienced in treating urethral cancer?
  • Are there any clinical trials I could join?

Resources

  1. Gakis, G. et al. (2013) ‘EAU guidelines on primary urethral carcinoma’, European Urology, 64(5), pp. 823-830.
  2. Janisch, F. et al. (2019) ‘Current disease management of primary urethral carcinoma’, European Urology Focus, 5(5), pp. 722-734.
  3. Lagarde-Lenon, M.S. and Aron, M. (2022) ‘Female urethral carcinoma: a contemporary review of the clinicopathologic features, with emphasis on the histoanatomic landmarks and potential staging issues’, Human Pathology, 129, pp. 71-80.
  4. Wei, Y. et al. (2017) ‘Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study’, OncoTargets and Therapy, 10, pp. 3381-3389.
  5. National Cancer Institute (2026) Urethral Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/urethral/hp/urethral-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.